Consensus Superiority of the Pharmacophore-Based Alignment, Over Maximum Common Substructure (MCS): 3D-QSAR Studies on Carbamates as Acetylcholinesterase Inhibitors

In view of the nonavailability of complete X-ray structure of carbamates cocrystallized with AChE enzyme, the 3D-QSAR model development based on cocrystallized conformer (CCBA) as well as docked conformer-based alignment (DCBA) is not feasible. Therefore, the only two alternatives viz. pharmacophore and maximum common substructure-based alignments are left for the 3D-QSAR comparative molecular field analyses (CoMFA) and comparative molecular similarity indices analyses (CoMSIA) model development. So, in the present study, the 3D-QSAR models have been developed using both alignment methods, where CoMFA and CoMSIA models based on pharmacophore-based alignment were in good agreement with each other and demonstrated significant superiority over MCS-based alignment in terms of leave-one-out (LOO) cross-validated q(2) values of 0.573 and 0.723 and the r(2) values of 0.972 and 0.950, respectively. The validation of the best CoMFA and CoMSIA models based on pharmacophore (Hip-Hop)-based alignment on a test set of 17 compounds provided significant predictive r(2) [r(2)(pred(test))] of 0.614 and 0.788, respectively. The contour map analyses revealed the relative importance of steric, electrostatic, and hydrophobicity for AChE inhibition activity. However, hydrophobic factor plays a major contribution to the AChE inhibitory activity modulation which is in strong agreement with the fact that the AChE is having a wide active site gorge (approximately 20 A) occupied by a large number of hydrophobic amino acid residues.

[1]  Gerhard Klebe,et al.  Comparative Molecular Similarity Index Analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries , 1999, J. Comput. Aided Mol. Des..

[2]  N. Ariel,et al.  Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket. , 1993, The Journal of biological chemistry.

[3]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[4]  M. Zoli,et al.  Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis , 2002, Neuroscience.

[5]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[6]  Kazuo Koyama,et al.  A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. , 2003, Bioorganic & medicinal chemistry.

[7]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[8]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[9]  P. Walsh.  Ageing and health issues in intellectual disabilities , 2005, Current opinion in psychiatry.

[10]  J. Kirsch,et al.  Fractional diffusion-limited component of reactions catalyzed by acetylcholinesterase. , 1986, Biochemistry.

[11]  Gyanendra Pandey,et al.  3D QSAR Studies on Protein Tyrosine Phosphatase 1B Inhibitors: Comparison of the Quality and Predictivity among 3D QSAR Models Obtained from Different Conformer-Based Alignments , 2006, J. Chem. Inf. Model..

[12]  N Butters,et al.  Clinical assessment of memory disorders in amnesia and dementia. , 1995, Annual review of psychology.

[13]  P. Deyn,et al.  Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model , 2005, Psychopharmacology.

[14]  H. Kubinyi,et al.  3D QSAR in drug design. , 2002 .

[15]  C. Barnes,et al.  Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors , 2000, Neuroscience.

[16]  E. Giacobini.  Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease , 2003, Neurochemical Research.

[17]  A. Tropsha,et al.  Beware of q 2 , 2002 .

[18]  V. Prasher,et al.  Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population , 2004, International journal of geriatric psychiatry.

[19]  A Tropsha,et al.  Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. , 1996, Journal of medicinal chemistry.

[20]  P. Taylor,et al.  Expression of recombinant acetylcholinesterase in a baculovirus system: kinetic properties of glutamate 199 mutants. , 1992, Biochemistry.

[21]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[22]  Andrew Smellie,et al.  Analysis of Conformational Coverage, 1. Validation and Estimation of Coverage , 1995, J. Chem. Inf. Comput. Sci..

[23]  Yvonne C. Martin,et al.  A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists , 1993, J. Comput. Aided Mol. Des..

[24]  A K Saxena,et al.  Comparison of MLR, PLS and GA-MLR in QSAR analysis* , 2003, SAR and QSAR in environmental research.

[25]  S. Marumoto,et al.  Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. , 2003, Bioorganic & medicinal chemistry.

[26]  Tudor I. Oprea,et al.  Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules. , 1993, Journal of medicinal chemistry.

[27]  H. Boddeke,et al.  Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. , 1993, Progress in brain research.

[28]  J. Buccafusco,et al.  The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development , 2003, Journal of Pharmacology and Experimental Therapeutics.

[29]  N. Waugh,et al.  Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. , 2001, Health technology assessment.

[30]  Hugo Kubinyi,et al.  3D QSAR in drug design : theory, methods and applications , 2000 .

[31]  Anshuman Dixit,et al.  An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis. , 2008, Journal of molecular graphics & modelling.

[32]  C. Lanni,et al.  Acetylcholinesterase inhibitors: novel activities of old molecules. , 2004, Pharmacological research.

[33]  G Klebe,et al.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.

[34]  G. Naglie,et al.  Galantamine vs Donepezil in the Treatment of Alzheimer’s Disease , 2003, Drugs & aging.

[35]  A. Goldman,et al.  Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.